Check-Cap (NASDAQ:CHEK) Coverage Initiated at assumed coverage on shares of Check-Cap (NASDAQ:CHEKGet Rating) in a research note published on Wednesday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

NASDAQ:CHEK opened at $2.91 on Wednesday. The stock’s 50 day moving average price is $3.32 and its two-hundred day moving average price is $4.12. Check-Cap has a 12-month low of $1.88 and a 12-month high of $9.20.

Hedge Funds Weigh In On Check-Cap

An institutional investor recently raised its position in Check-Cap stock. Citadel Advisors LLC grew its position in Check-Cap Ltd. (NASDAQ:CHEKGet Rating) by 51.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 141,319 shares of the medical research company’s stock after purchasing an additional 47,868 shares during the quarter. Citadel Advisors LLC owned about 0.15% of Check-Cap worth $41,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 17.59% of the company’s stock.

Check-Cap Company Profile

(Get Rating)

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer.

Recommended Stories

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with's FREE daily email newsletter.